The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib verses treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.
Clinical Trial Information
Trial Contact: Rompola, Melissa; Ferry, Robert, P.
Age Group: Adult
Phase: Drug: Phase III
Principal Investigator: Julio J. Hajdenberg, MD
Sub Investigators: Daniel Ari Landau, MD;
IRB No: 17.007.01
Secondary Protocol No: CO-338-063
Applicable Disease Sites: Metastatic Castration Resistant Prostate Cancer